Literature DB >> 16175180

NF-kappaB: linking inflammation and immunity to cancer development and progression.

Michael Karin1, Florian R Greten.   

Abstract

There has been much effort recently to probe the long-recognized relationship between the pathological processes of infection, inflammation and cancer. For example, epidemiological studies have shown that approximately 15% of human deaths from cancer are associated with chronic viral or bacterial infections. This Review focuses on the molecular mechanisms that connect infection, inflammation and cancer, and it puts forward the hypothesis that activation of nuclear factor-kappaB (NF-kappaB) by the classical, IKK-beta (inhibitor-of-NF-kappaB kinase-beta)-dependent pathway is a crucial mediator of inflammation-induced tumour growth and progression, as well as an important modulator of tumour surveillance and rejection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175180     DOI: 10.1038/nri1703

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  1150 in total

1.  Down-regulation of testes-specific protease 50 induces apoptosis in human laryngocarcinoma HEp2 cells in a NF-κB-mediated pathway.

Authors:  Yu-Lin Liu; Ya-Nan Sun
Journal:  Mol Biol Rep       Date:  2014-11-16       Impact factor: 2.316

2.  Increased expression of TLR-2, COX-2, and SOD-2 genes in the peripheral blood leukocytes of opisthorchiasis patients induced by Opisthorchis viverrini antigen.

Authors:  Puangrat Yongvanit; Raynoo Thanan; Somchai Pinlaor; Paiboon Sithithaworn; Watcharin Loilome; Nisana Namwat; Anchalee Techasen; Somkid Dechakhamphu
Journal:  Parasitol Res       Date:  2011-12-09       Impact factor: 2.289

3.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

4.  Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity.

Authors:  Andrew H Coles; Hugh Gannon; Anna Cerny; Evelyn Kurt-Jones; Stephen N Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 5.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

6.  Dietary Inflammatory Index and Site-Specific Cancer Risk: A Systematic Review and Dose-Response  Meta-Analysis.

Authors:  Ahmad Jayedi; Alireza Emadi; Sakineh Shab-Bidar
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

Review 7.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis.

Authors:  L Ouyang; Z Shi; S Zhao; F-T Wang; T-T Zhou; B Liu; J-K Bao
Journal:  Cell Prolif       Date:  2012-10-03       Impact factor: 6.831

Review 8.  Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.

Authors:  Thorsten Hagemann; Subhra K Biswas; Toby Lawrence; Antonio Sica; Claire E Lewis
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

9.  Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.

Authors:  Hee Chul Park; Nora A Janjan; Tito R Mendoza; Edward H Lin; Saroj Vadhan-Raj; Mandeep Hundal; Yiqun Zhang; Marc E Delclos; Christopher H Crane; Prajnan Das; Xin Shelley Wang; Charles S Cleeland; Sunil Krishnan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

10.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.